Welcome to our dedicated page for Nutriband SEC filings (Ticker: NTRBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the regulatory trail behind Nutriband’s abuse-deterrent AVERSA patch means wading through technical exhibits, clinical timelines, and warrant conversions. Investors don’t have days to get Nutriband SEC filings explained simply—they need answers now. Whether you’re checking if the Phase 1 study advanced or if new patents were granted, Stock Titan pinpoints the exact paragraph inside each disclosure and converts dense language into plain English.
Our platform ingests every Nutriband quarterly earnings report 10-Q filing moments after it hits EDGAR, flags cash-burn shifts, and stacks them beside the Nutriband annual report 10-K simplified for year-over-year context. Real-time alerts surface Nutriband Form 4 insider transactions real-time and headline any Nutriband 8-K material events explained, so you don’t miss licencing deals or FDA feedback. Behind the scenes, AI scores sentiment, extracts segment revenue, and links each metric to the original line item—no spreadsheets required.
Use these insights to run a Nutriband earnings report filing analysis, monitor Nutriband insider trading Form 4 transactions before material catalysts, or compare Nutriband executive stock transactions Form 4 against peer behavior. If compensation structures matter, the Nutriband proxy statement executive compensation section is pre-tagged and summarized. In short, understanding Nutriband SEC documents with AI means faster due diligence, fewer blind spots, and better-timed decisions—especially when safety-focused innovation moves the share price.
Nutriband Inc. reported continued operating losses and liquidity activity for the six months ended July 31, 2025. The company recorded a net loss of $3,416,710 for the six-month period and used $2,650,313 of cash from operations. Total goodwill remained $1,719,535. Inventory was $138,031 (work-in-process $8,061; finished goods $8,042; raw materials $121,477). The company completed an $8,400,000 equity financing on April 19, 2024 and received $5,305,503 from warrant exercises during the six months ended July 31, 2025. A related-party credit line facility of $5,000,000 (originally $2,000,000) is available; advances bear 7% interest and are due March 19, 2026. The company has operating losses since inception and relies on equity sales and debt to fund operations.
Form 8-K highlights
On 5 Aug 2025 Nutriband (Nasdaq: NTRB) completed a stock dividend of 3,008,643 Series A Convertible Preferred shares, issuing one preferred share for every four common shares held as of 25 Jul 2025 (fractions rounded down). The distribution is treated as an unregistered sale under Item 3.02.
Item 5.03 notes that the board, without shareholder vote, amended the Articles of Incorporation on 9 Jul 2025 to create the Series A non-voting preferred class (par $0.001). Authorised shares were first set at 2.79 m and later increased to 10 m via a Certificate of Correction filed 21 Jul 2025.
The preferred shares will convert 1-for-1 into common stock only after FDA approval of AVERSA-based transdermal products. Until conversion eligibility and SEC/Nasdaq registration are complete, the shares are restricted and held by transfer agent Equiniti. Holders may receive dividends declared on either preferred or common stock. Exhibits 3.1D and 3.1E contain the charter amendment and correction.
Nutriband Inc. (Nasdaq: NTRB/NTRBW) has filed Post-Effective Amendment No. 6 to its Form S-1 to keep current the registration of 957,980 unexercised IPO warrants issued on October 1, 2021. Each warrant is immediately exercisable at $6.43 per share and expires on October 1, 2026. The filing enables the company to continue issuing registered common shares to warrant holders, or to honor cashless exercises if a registration statement is not effective.
Key highlights:
- Outstanding warrants: 957,980
- Warrants already exercised: 458,820, generating net proceeds of $2,954,561
- Exercise price: $6.43 per share (in-the-money versus the June 18, 2025 closing price of $7.79)
- Expiry date: Five years from original issuance, October 1, 2026
- Potential dilution: Up to 957,980 additional common shares if all remaining warrants are exercised
- Risk disclosure: Extensive FDA approval, manufacturing and distribution risks highlighted beginning on page 4
The company reiterates that it qualifies as a non-accelerated filer, smaller reporting company and emerging growth company, and it has elected to use the extended transition period for new accounting standards. Proceeds from any future warrant exercises would provide additional, non-dilutive (cash) financing, but existing shareholders face dilution upon share issuance. No new financial statements or earnings data are included in this amendment.
FAQ
What is the current stock price of Nutriband (NTRBW)?
